Tech Company M&A Transactions
Benevir Acquisition
Benevir, based in Gaithersburg, was acquired by Janssen Biotech. What Janssen Biotech paid for Benevir was not announced.
Transaction Overview
Company Name
Acquired By
Announced On
5/2/2018
Transaction Type
M&A
Amount
Unknown
M&A Terms
BeneVir engineers oncolytic viruses through the T-Stealth� platform to overcome the barrier of the body's immune system. Janssen intends to advance pre-clinical candidates as standalone therapies and in combination with other immunotherapies for the treatment of solid tumor cancers (e.g., lung, prostate, colorectal, etc.). Financial terms of the transaction were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
708 Quince Orchard Rd. 150
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
The BeneVir oncolytic virus platform is based on T-StealthTM technology, which overcomes a major barrier to the clinical success of oncolytic viruses.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Matthew Mulvey
Chief Scientific Officer
Ian Mohr
Founder
Katherine Sacksteder
VP - R & D
Steven Fuhrmann
Browse more venture capital transactions:
Prev: 5/2/2018: Humu venture capital transaction
Next: 5/2/2018: Hustle venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on all VC transactions involving tech companies. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs